1P-LSD
1P-LSD is a chemical relative of LSD that acts as a prodrug — the body converts it into LSD — so its effects are essentially indistinguishable from LSD. It is not scheduled by name in the US but is prosecutable as an LSD analogue under the Federal Analogue Act, and is explicitly banned in many other countries.
Overview
1P-LSD (1-propionyl-LSD) is a semi-synthetic psychedelic of the lysergamide family, first sold online as a designer drug in 2015 as a legal alternative to LSD. It differs from LSD by a single added chemical group and functions as a prodrug: once in the body it is converted to LSD. It is typically sold on blotter, closely mirroring how LSD is distributed.
Source: Wikipedia (CC-BY-SA); peer-reviewed literature (NIH/PMC)
Chemistry & mechanism of action
1P-LSD is understood to act as a prodrug for LSD — it is metabolized into LSD in the body — so its ultimate mechanism is LSD's: agonism at serotonin 5-HT2A receptors, which produces the psychedelic effects. A human pharmacokinetic study found its subjective effects and time course closely track those of LSD, consistent with the prodrug model.
Source: peer-reviewed literature (NIH/PMC); Wikipedia (CC-BY-SA)
Effects
Because it converts to LSD, the effects are essentially those of LSD: visual distortions, altered thought and perception, emotional intensity, and altered sense of time, typically lasting many hours. Onset is reported as slightly slower than LSD. Anecdotally users find it hard to distinguish from LSD, though formal research is limited.
Source: peer-reviewed literature (NIH/PMC); Wikipedia (CC-BY-SA)
Risks & harms
As a prodrug of LSD, 1P-LSD carries LSD's risk profile. The main dangers are psychological: intensely distressing experiences, panic, and — in people vulnerable to psychiatric illness — the possibility of triggering prolonged difficulty, all worsened by an unsafe setting. It raises heart rate and blood pressure modestly and, as an ergoline-derived compound, can cause vasoconstriction. Combining it with serotonergic drugs such as SSRIs, MAOIs, or other psychedelics/stimulants raises the risk of serotonin syndrome. A specific hazard of the research-chemical market is dosing and identity: blotter can vary in strength, and a product sold as 1P-LSD may be a different, more dangerous compound (for example the NBOMe class, which can be fatal at blotter-sized amounts). There is no way to confirm identity or dose by eye. Anyone with a severe psychiatric crisis, chest pain, high fever with rigidity, or seizures needs emergency care — call 911, and Poison Control at 1-800-222-1222 can advise. This page has not yet been medically reviewed.
Source: peer-reviewed literature (NIH/PMC); SAMHSA; Wikipedia (CC-BY-SA)
Legal status (US)
In the United States, 1P-LSD is not listed by name on any DEA schedule. However, because it is structurally and pharmacologically similar to LSD — a Schedule I substance — and acts as an LSD prodrug, it can be treated as a Schedule I controlled substance under the Federal Analogue Act when intended for human consumption; the same penalties that apply to LSD then apply to it. Vendors commonly label it 'not for human consumption' to sidestep this, a distinction courts have not reliably accepted. It is explicitly banned in many countries (including the UK and Germany). Follow local law; consult DEA resources for specifics. This page has not yet been medically reviewed.
Source: DEA; US federal law (Federal Analogue Act, 21 U.S.C. 813); Wikipedia (CC-BY-SA)
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With psychedelics, fear and confusion are usually temporary. Change your surroundings, calmer light, quiet music, a trusted person, and remind yourself it will lift as the drug wears off.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 119025985PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- (6aR,9R)-N,N-diethyl-7-methyl-4-propanoyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamidePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C23H29N3O2PubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CCC(=O)N1C=C2C[C@@H]3C(=C[C@H](CN3C)C(=O)N(CC)CC)C4=C2C1=CC=C4PubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- JSMQOVGXBIDBIE-OXQOHEQNSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- 1-Propionyl-lsd, 1P-LADPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- Unknown — pending review (no Rx/OTC label; illicit — pill visuals = FIRST-PARTY submissions only, never generated or scraped)
- Route
- Unknown — pending review
- Shape
- Unknown — pending review
- Color
- Unknown — pending review
- Imprint
- Unknown — pending review
- Score
- Unknown — pending review
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- 1P-LSD (1-propionyl-LSD) is a research-chemical analogue of LSD that acts as a prodrug — the body converts it into LSD — so its effects are essentially those of LSD itself: vivid visual distortion, altered thought and mood, synaesthesia and a long duration. It emerged as a "legal" or grey-market alternative to LSD, sold on blotter much like it, and is generally reported to be very close to LSD in potency and character.PubChem CID 119025985 ↗ · retrieved 2026-06-18
- Risks
- Because 1P-LSD is converted to LSD in the body, its risks are LSD's: frightening or overwhelming experiences (panic, paranoia), impaired judgment over a long duration that raises accident risk, raised heart rate and blood pressure, and — in vulnerable people — the possibility of persistent psychiatric effects or hallucinogen persisting perception disorder. The added uncertainty is that it is an unregulated research chemical, so its purity and dose are not guaranteed, and it may be mis-sold as or mistaken for LSD or other blotter compounds — its contents cannot be assumed without testing.PubChem CID 119025985 ↗ · retrieved 2026-06-18
- Interactions
- Unknown, pending review
Dosage
Pending medical reviewer